Ligand Pharmaceuticals | LGND - Current Liabilities


Ligand Pharmaceuticals reported $46.74M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Enviri Corporation USD 640.69M 6.67M Mar/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck USD 27.73B 786M Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 62.74M 6.62M Jun/2026